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OBJECTIVES: The objectives of this study were 1) to
compare average total daily study drug cost of risperidone
(n = 120), olanzapine (n = 153), and quetiapine (n = 54)
used as treatment for schizophrenia or schizoaffective 
disorder during an inpatient hospitalization, and 2) to
compare medication utilization.
METHODS: Retrospective data on inpatient drug uti-
lization were collected on 327 patients at three acute
inpatient mental health facilities through 60 days follow-
ing initiation of study drug. All patients with an available
psychiatric history had at least one previous psychiatric
hospitalization. A propensity scoring method, modiﬁed
for three treatment groups, was used to adjust for treat-
ment selection bias. Factors which predicted treatment
selection for all study drugs, for which adjustments were
made, included age, gender, race, and facility.
RESULTS: The average daily study drug cost was $4.35
less for risperidone than olanzapine (95% CI -$5.84, 
-$2.86), and $1.41 less for risperidone than quetiapine
(95% CI -$3.89, $0.81). Between groups, there were 
no statistically signiﬁcant differences in length of stay.
Average daily dose for patients on study drug at time of
discharge was 4.85mg (SD 2.29) for risperidone, 14.22
mg (SD 5.44) for olanzapine, and 368.64mg (SD 230.52)
for quetiapine. Total daily drug cost, including study drug
and concomitant medications, for patients on study drug
at time of discharge was $12.07 (SD 6.53) for risperidone,
$16.33 (SD 6.56) for olanzapine, and $20.22 (SD 42.42)
for quetiapine.
CONCLUSIONS: Using a study design and analysis
aimed at minimizing treatment selection bias, risperidone
patients had a lower daily inpatient study drug cost than
olanzapine (statistically signiﬁcant) and quetiapine (not
statistically signiﬁcant) patients. In addition, differences
in concomitant medication cost and utilization were
present among treatment groups.
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Bipolar disorder is one of the most costly psychiatric 
disorders to treat.
OBJECTIVE: This analysis focuses on (direct) cost out-
comes of a multi-center, randomized, double-blind clini-
cal trial comparing efﬁcacy, safety, effectiveness, and costs
of two ﬁrst-line treatments in acute mania, olanzapine
versus divalproex.
METHODS: The original study included 251 inpatients
with a diagnosis of bipolar I disorder, in an acute manic
or mixed episode. Hospitalization was required for the
ﬁrst week of double-blind treatment, with subsequent 
discharge if clinically appropriate. Inpatient and outpa-
tient resource utilization data were collected at the end 
of the acute phase of the trial (3 weeks), and during 
the maintenance phase (weeks 7, 15, 23, 31, 39, and 47).
Costs were analyzed for all patients who entered the
maintenance phase (olanzapine n = 77, divalproex n =
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